Of course! A blood test called the Carcinoembryonic Antigen (CEA) test, also known as “oncofetal monitoring,” measures the amount of a protein called CEA, which is sometimes found in higher concentrations in people who have certain cancers, including colorectal cancer but also some gastrointestinal, breast, lung, and thyroid cancers. Because of its non-specificity, it is mostly used to track the effectiveness of treatment and identify cancer recurrences, not as a primary diagnostic technique.
The CEA test’s description of “health heart diagnostics” (healthesh) highlights the need for a complete strategy to monitoring cancer patients, who may also experience cardiovascular problems as a side effect of cancer treatment or as a result of the cancer itself. For example, certain cancer treatments may affect the heart